arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ADC Therapeutics SA

ADCT
$1.13 ▲ +0.01 (+0.89%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Neutral
auto_awesome

Analytical Summary

ADC Therapeutics SA shows mixed fundamentals. On the positive side, Return on Common Equity (%) remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $174.2M
Dividend Yield
Revenue Growth -9.5%
Op. Margin -121.1%
ROIC 11.7%
FCF / Share $-0.19
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.85M
↓ -9.5%
Net Income Profit after all expenses
$-32.97M
↑ +14.6%
Operating Margin Operating profit as % of sales
-121.1%
↓ -55.8% 1th
FCF / Share Free cash flow per share
$-0.19
↑ +63.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
98
Financial Health
33
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 17 quarters